S_Franconi Posted - 4 days ago

$IMTX The company focuses on developing T-cell receptor-based immunotherapies for solid tumors with unmet medical needs. Immatics has partnerships with Bristol Myers Squibb, Moderna, and Editas, and is advancing multiple candidates in clinical studies. https://seekingalpha.com/article/4687012-immatics-big-pharma-partners-intriguing-catalysts-make-buy-case-imtx-stock

dhovekamp42 Posted - 04/19/24

@Apr4609 @MagicPills also noteworthy the comments regarding PRAME TCR with multiple upcoming data from Adaptimmune competitors $IMTX Immatics and former sister company $IMCR Immunocore

dhovekamp42 Posted - 04/19/24

@Rabinovich @Thomasdina if $ADAP will do raise so Mizuho will not be alone - listen to the analyst talking about at the Adaptimmune "investor day" and also PRAME as a TCR target at competitors $IMCR Immunocore and $IMTX Immatics https://x.com/dhovekamp42/status/1781151777687064820

dhovekamp42 Posted - 04/12/24

@BioCrEq @Whtmtn $ADAP MAGE A4 CD8+ (Uza-cel) is currently scheduled for next decisions at the end of the year in head & neck / urothelial cancers and a time horizont of 2028 for first approval of Uza-cel in ovarian - PRAME targeting plans will have to wait for the outcome of the front runners $IMCR, $IMTX, and $BNTX

bostondaytrader Posted - 04/09/24

$EDBL - Looking really good here. Adding more... My biggest play is: $IMTX ( This stock is showing up with big positions in 13fs... Such a solid BIO stock. And, we were oversold and now crossing back over. Good luck, boys! ) Here are my other plays: $CTX.X $XTZ.X $LTC.X

bostondaytrader Posted - 04/09/24

$IMTX - This stock is showing up with big positions in 13fs... Such a solid BIO stock. And, we were oversold and now crossing back over. Good luck, boys! Here are my other plays: $BMR $SAVA $DJT (back in here).

bostondaytrader Posted - 04/09/24

$IMTX - This is an easy 8-10 Bagger. Such a solid BIO stock. Good luck, boys! This is going to CRUSH and it's also oversold so ready to pop with volume. Here are my other plays: $JAN $CSTE $ACRV

G101SPM Posted - 04/08/24

@S_Franconi per request: $IMTX at $10.58 carries SPM 81.24 tag for the short term suggesting a neutral stance with limited upside. Long term IMTX carries SPM 86.88 tag with target at $16.00.

S_Franconi Posted - 04/07/24

$IMTX @G101SPM Can you run this one?

StockInvest_us Posted - 1 month ago

Signal alert: $IMTX - Oversold Trend Short (Undervalued) https://stockinvest.us/l/hmSbNIjtvM

RamenLives Posted - 1 month ago

$IMTX @G101SPM hello, can you please run this one? Thanks

zztopps Posted - 03/27/24

$IMTX Same pattern for many clinical oncology bios, early strength fades late in the day. Frustrating. But fundamentals remain intact.

epsguid Posted - 03/21/24

$IMTX reported a loss of $0.32, consensus was ($0.41) via @eWhispers #epsbeat http://eps.sh/d/imtx

DonCorleone77 Posted - 03/21/24

$IMTX Immatics sees cash runway into 2027 Cash and cash equivalents as well as other financial assets total EUR 425.9 million as of December 31, 2023, compared to EUR 362.2 million as of December 31, 2022. The increase is mainly due to upfront payments for collaborations, partly offset by our ongoing research and development activities. This does not include the net proceeds received in January 2024 from the public offering. Adding these proceeds, the company currently projects a cash runway into 2027.

DonCorleone77 Posted - 03/21/24

$IMTX Immatics reports 2023 EPS (EUR 1.20) vs. EUR 0.55 last year Reports revenue EUR 53.9M vs. EUR 172.8M last year. "Immatics kicked off 2024 with a successful capital raise, providing significant financial runway and additional momentum to advance our ongoing clinical cell therapy and bispecific trials," said Harpreet Singh, Ph.D., CEO and Co-Founder of Immatics. "We are striving to reach multiple relevant milestones this year, including announcing clinical proof-of-concept for our half-life extended TCR Bispecifics platform. In parallel, the clinical data for our PRAME cell therapy, IMA203 GEN1, in conjunction with highly constructive FDA discussions, reinforces our confidence in advancing this asset toward a registration-enabling Phase 2/3 clinical trial in melanoma, while laying the groundwork to transition into a fully equipped commercial-stage company."

Stock_Titan Posted - 03/21/24

$IMTX Immatics Announces Full Year 2023 Financial Results and Corporate Update https://www.stocktitan.net/news/IMTX/immatics-announces-full-year-2023-financial-results-and-corporate-02yece4nx1nt.html

lkhoury Posted - 03/20/24

$IMTX is moving

NinjaXLightning Posted - 03/14/24

$EDIT So about 6 months after $BMY started a collaboration with $IMTX, Editas a collaboration with Immatics also.

RamenLives Posted - 03/12/24

$IMTX

RamenLives Posted - 03/08/24

$IMTX Be nice if the company put out some news here.

RamenLives Posted - 2 months ago

$IMTX In

AltecBX Posted - 2 months ago

$IMTX watch the breakout

RonIsWrong Posted - 02/29/24

$IMTX let's see now...

techj2022 Posted - 02/24/24

$IMTX PRAME is a validated target. its pipeline looks very promising. weekly candle looks highly constructive. needs to break 13 for a breakout. expect valuation gap with $imcr to narrow.

NJgolfer Posted - 02/23/24

$IMTX need some weakness to provide a pullback to get in. Their pipeline is strong as well as financial backing. But a ways off from milestones.

fessr Posted - 02/23/24

$IMTX

S_Franconi Posted - 02/18/24

$IMTX I like it.

Doozio Posted - 02/17/24

$IMTX weekly bullish engulfer while XBI is in da chop chop huckleberries during 🧠⏰

techj2022 Posted - 02/12/24

$IMTX bullish cup w handle on weekly. only one of 2 bios targeting PRAME, the other one is $IMCR

Doozio Posted - 01/28/24

$IMTX a 🧠👀 is NOW 🧠⏰. Chop chop huckleberries….